Ticker Details
Alkermes plc Ordinary Shares Alkermes PLC is a fully integrated, biopharmaceutical company. It applies its scientific expertise and proprietary technologies to research, develop and commercialize pharmaceutical products to address unmet medical needs of patients.
IPO Date:	August 1, 1991
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$6.13B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.49 | 1.86%
Avg Daily Range (30 D):	$0.55 | 1.57%
Avg Daily Range (90 D):	$0.55 | 1.70%

Institutional Daily Volume
Avg Daily Volume:	1.09M
Avg Daily Volume (30 D):	1.55M
Avg Daily Volume (90 D):	1.81M

Trade Size
Avg Trade Size (Sh.):	114
Avg Trade Size (Sh.) (30 D):	61
Avg Trade Size (Sh.) (90 D):	67

Institutional Trades
Total Institutional Trades:	14,362
Avg Institutional Trade:	$2.59M
Avg Institutional Trade (30 D):	$3.67M
Avg Institutional Trade (90 D):	$3.87M
Avg Institutional Trade Volume:	.09M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$5.48M
Avg Closing Trade (30 D):	$11.16M
Avg Closing Trade (90 D):	$11.98M
Avg Closing Volume:	184.8K

News

Feb 23, 2026 @ 3:26 PM Viridian Therapeutics Stock Up 75%, but One Fund J... Source: Jonathan Ponciano

Feb 23, 2026 @ 3:18 PM Spyre Therapeutics Stock Surges This Past Year as ... Source: Jonathan Ponciano

Feb 10, 2026 @ 9:05 PM Avadel Pharmaceuticals Announces Outcome of the Co... Source: Globe Newswire

Jan 12, 2026 @ 9:05 PM Avadel Pharmaceuticals Announces that Avadel Share... Source: Globe Newswire

Dec 3, 2025 @ 9:47 PM Announcement relating to despatch of Definitive Pr... Source: Globe Newswire

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$.93	$-.4	$.3
Diluted EPS	$.9	$-.4	$.29
Revenue	$1.56B	$392.91M	$384.55M
Gross Profit	$1.35B	$331.33M	$338.34M
Net Income / Loss	$152.72M	$-66.48M	$49.34M
Operating Income / Loss	$191.88M	$-48.28M	$58.1M
Cost of Revenue	$208.84M	$61.58M	$46.21M
Net Cash Flow	$-48.25M	$-768.22M	$503.33M
PE Ratio

Splits
May 15, 2000	2:1